Drug Discovery & Development
Eli Lilly acquiring immune therapy developer Dice Therapeutics for $2.4B
Eli Lilly said this week it has inked an agreement to acquire Dice Therapeutics, a biopharma firm developing novel oral therapeutic candidates, for $2.4 billion in cash. Read More
Future Fields, Jenthera Therapeutics collaborate to develop novel protein for the delivery of cancer biologics
Biotech firm Future Fields and gene-editing firm Jenthera Therapeutics this week announced a collaboration focused on the manufacturing of a first-of-its-kind cancer-fighting protein. Read More
Conferences
Science Briefs
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter